rhPTH (1-34) (Teriparatide for Injection) is contraindicated in the following patients: Hypersensitivity to teriparatide or to any of the excipients of this product. Pre-existing hypercalcaemia. Severe renal impairment. Metabolic bone diseases other than primary osteoporosis (including Hyperparathyroidism and Paget’s disease of bone). Unexplained elevations of alkaline phosphatase. Prior external beam or implant radiation therapy to the skeleton. Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
